Educational Articles

Loading...
Accelerate your knowledge of stocks, funds, options, convertibles and the economy.  Get the most from Value Line research through must-read articles that make you a smarter investor.


Daily Updates/ Market Daily Updates

Stock Market Today: July 30, 2019

7/30/2019 9:12:08 AM The marketsstarted out negatively today, as a few worrisome earnings reports from companies were released both yesterday and before the bell this morning. These chilled the market some. Additionally, concerns increased about U.S. trade negotiations with China, due to fears regarding the timing and even likelihood of an eventual deal. All told, the Dow closed down 23 points, the S&P 500 finished lower by eightpoints, and the NASDAQ fell 37 points.
read more

Highlights/ StockHighlights

Dow 30 Earnings: Pfizer Second Quarter 2019

7/29/2019 12:30:33 PM New York-based drugmaker and Dow-30 component Pfizer (PFE) reported second-quarter GAAP earnings of $0.89 a share, versus $0.65 in the comparable period of 2018. The year-over-year improvement was fueled primarily by reduced production costs (-12%) and lower taxes, which helped to offset a modest decline in total revenues. Meantime, adjusted earnings, which exclude one-time gains, losses, and other nonrecurring items, and are more closely followed by Wall Street, came in at $0.80 a share, versus $0.77 in Q2, 2018.
read more

Highlights/ StockHighlights

Dow 30 Earnings: Pfizer First Quarter 2019

4/30/2019 11:55:12 AM Drugmaker and Dow-30 component Pfizer reported better-than-anticipated March-period earnings. Investors,encouraged by the biopharma portfolio, bid the stock up slightly in early trading.
read more

Highlights/ StockHighlights

Dow 30 Earnings: Pfizer Fourth Quarter 2018

1/29/2019 1:02:13 PM New York-based drugmaker and Dow-30 component Pfizer (PFE) reported a fourth-quarter GAAP loss of $0.07 a share, versus earnings of $2.02 in the comparable period of 2017. While revenues inched up a few percentage points year to year (more below), a sharp increase in restructuring costs and significant asset impairment charges weighed heavily on the bottom-line tally. The comparison was further skewed by a massive tax benefit ($1.79 a share) realized in fourth quarter of 2017. Meantime, adjusted earnings, which exclude one-time gains, losses, and other nonrecurring items, and are more closely followed by Wall Street, came in at $0.64 a share, versus $0.62 last year.
read more

Highlights/ StockHighlights

Dow 30 Earnings: Pfizer Third Quarter 2018

10/30/2018 11:40:48 AM Drugmaker and Dow-30 component Pfizer reported mixed third-quarter results, and the stock headed lower.
read more

Highlights/ StockHighlights

Dow 30 Earnings: Pfizer Second Quarter 2018

7/31/2018 12:13:10 PM New York-based drugmaker and Dow-30 component Pfizer (PFE) reported second-quarter earnings of $0.65 a share, versus $0.51 in the comparable period of 2017. The year-over-year improvement was driven primarily by reduced taxes (-12%) and higher revenues (+4%), partially offset by increased costs tied to production (+10%) and SG&A (+3%).
read more

Highlights/ StockHighlights

Dow 30 Earnings: Pfizer First Quarter 2018

5/1/2018 12:01:19 PM New York-based drugmaker and Dow-30 component Pfizer (PFE) reported first-quarter earnings of $0.59 a share, versus $0.51 in the comparable period of 2017. The year-over-year improvement was driven primarily by reduced taxes, lower restructuring charges, and a modest top-line advance (+1%), partially offset by increased production (+4%), SG&A (+3%), and research & development (+2%) costs.
read more

Highlights/ StockHighlights

Dow 30 Earnings: Pfizer Fourth Quarter 2017

1/30/2018 12:03:36 PM Drugmaker and Dow-30 component Pfizer reported better-than-expected December-quarter earnings, but the stock pulled back 2% following the release.
read more

Highlights/ StockHighlights

Dow 30 Earnings: Pfizer Third Quarter 2017

10/31/2017 11:13:03 AM Drugmaker and Dow-30 component Pfizer reported better-than-expected September-quarter earnings, but the stock pulled back slightly following the release.
read more

PAGE
OF 12